

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

**Functional analysis of PaxP and PaxQ,
two cytochrome P450 monooxygenases required for
paxilline biosynthesis in *Penicillium paxilli***

A Thesis presented in partial fulfilment of
the requirements for the degree of
Master of Science in Genetics
at Massey University, Palmerston North,
New Zealand.

Rohan George Thomas Lowe

2002

Abstract

The indole-diterpene paxilline is a potent mammalian tremorgenic mycotoxin and a known inhibitor of maxi-K ion channels. The gene cluster encoding the enzymes for the synthesis of this compound was recently cloned from *Penicillium paxilli* (Young *et al.* 2001). The cluster comprises a set of core genes required for indole-diterpene biosynthesis, including two cytochrome P450 monooxygenases, *paxP* and *paxQ*. Targeted deletion of *paxP* and *paxQ* resulted in mutant strains that accumulate paspaline and 13-desoxypaxilline, respectively, confirming that both genes are involved in paxilline biosynthesis. The aim of the current work is to establish *in vitro* that PaxP and PaxQ catalyse the monooxygenation of paspaline and 13-desoxypaxilline, respectively. To achieve this, cDNA copies of both genes were cloned into pGEX-6P-3, to generate pRL2 and pRL4, and the corresponding glutathione-S-transferase (GST) fusion proteins over-expressed in *E. coli*. However, both GST-fusion proteins accumulated as insoluble inclusion bodies when cultures were incubated at 18°C, 25°C and 37°C. Attempts to express a soluble form of the GST-PaxP by co-expressing this fusion with the chaperones, GroES and GroEL, or by expressing in *E. coli*, Origami B, a strain (*trxB*, *gor*, *lacY*) designed to facilitate expression of active and soluble proteins, were unsuccessful. GST-PaxP was able to be solubilised by the addition of 0.25% *N*-laurylsarcosine, and retained some glutathione binding activity, however, the yield was too low to carry out further experiments. GST and thioredoxin fusion expression constructs were designed in which the putative N-terminal trans-membrane region of PaxP and PaxQ was removed to aid solubility in *E. coli*. These N-terminal modified fusion proteins were still expressed as insoluble protein.

Acknowledgments

Firstly I would like to acknowledge my supervisor Barry Scott. You have provided me with a fantastic lab to work in, and strong support throughout my study. I am particularly proud and appreciative that I began my research career in your lab.

I must also thank all the past and present lab members of Scott Base who I had the pleasure of working with. Lisa, you taught me everything about research and the lab environment when I arrived. You always had time for celebration and commiseration and I thank you for your time spent with me. Carolyn, you are the backbone of this lab and I am glad I had your experience as a resource during my study. However, science is not your only skill and I appreciate every beverage consumed and moment enjoyed at 14 Ascot Street. Jonathan, what would I have done without you? Probably been a hell of a lot more bored at the very least. I have had a great time in the lab and a lot of it is due to your friendship. We have shared plenty of good stories, good results, even more bad results and some great practical jokes. I appreciate every one. To Paula and Janet, thanks for good times and great friendship during your time in RB lab. I must also congratulate Andrea; you put up with my crappy jokes and schemes and yet always manage to have a smile on your face. Thank you.

I would like to thank Stan Moore for helping me with the design of N-terminal deletion constructs and multiple sequence alignments. I also thank Geoff Jameson and Gill Norris for advice on recombinant protein expression and Emily Parker for advice on metabolic chemistry.

To my family. Thanks for being supportive and providing me with something I can always look forward to when I manage a visit northward. I am proud of you all and I always work to be a son/brother you can be proud of.

I must also thank all the friends and flatmates who I have spent time with during my study. Special thanks go to James and Phillipa, you guys have always been there for me.

Thanks must also go to the all the people from the Institute of Molecular Biosciences who I have met and worked with along the way. There are a lot of you, but if you get a smile or greeting from me as we pass in the corridor, you know you are on the list!

Table of contents

Abstract	i
Acknowledgments	ii
Table of contents	iii
List of tables	xi
List of figures	xi

Chapter 1	Introduction	1
1.1	Indole-diterpenoids and paxilline	2
1.1.1	Paxilline biosynthesis	4
1.1.2	The paxilline biosynthetic gene cluster	11
1.2	Cytochrome P450 enzymes	12
1.2.1	The function of cytochrome P450 enzymes	12
1.2.2	Cytochrome P450 reductase	14
1.2.3	The cytochrome P450 reaction cycle.	14
1.3	Cytochrome P450 structural elements	16
1.3.1	The cytochrome P450 superfamily	16
1.3.2	Structural features of the cytochrome P450 enzyme	19
1.3.2.1	The haem binding region	20
1.3.2.2	Substrate binding regions	20
1.3.2.3	Eukaryotic cytochrome P450 enzymes	21

1.3.2.4	Membrane topology of cytochrome P450	21
---------	--------------------------------------	----

1.4 Sequence alignment of fungal cytochrome P450

enzymes. _____ 23

1.4.1	Sequence alignment construction	27
-------	---------------------------------	----

1.4.2	Cytochrome P450 secondary structure	27
-------	-------------------------------------	----

1.4.3	Redox partner interactions	29
-------	----------------------------	----

1.4.4	The substrate binding site	29
-------	----------------------------	----

1.5 Aim of this study _____ 30

Chapter 2 Materials and methods __ 31

2.1 Media _____ 33

2.1.1	Luria-Bertani medium	33
-------	----------------------	----

2.1.2	SOC medium	33
-------	------------	----

2.1.3	Media additions	33
-------	-----------------	----

2.1.3.1	Ampicillin	33
---------	------------	----

2.1.3.2	Chloramphenicol	33
---------	-----------------	----

2.1.3.3	IPTG	33
---------	------	----

2.1.3.4	Kanamycin	33
---------	-----------	----

2.1.3.5	Spectinomycin	34
---------	---------------	----

2.1.3.6	Tetracycline	34
---------	--------------	----

2.1.3.7	X-Gal	34
---------	-------	----

2.1.4	<i>E. coli</i> cell lines	34
-------	---------------------------	----

2.1.4.1	BL21	34
---------	------	----

2.1.4.2	Origami B	34
---------	-----------	----

2.1.4.3	Top10	34
---------	-------	----

2.1.4.4	XL1-blue	34
---------	----------	----

2.1.5	Plasmids	34
-------	----------	----

2.2 Common buffers _____ 36

2.2.1.1	PBS buffer	36
---------	------------	----

2.2.1.2	STE buffer	36
2.2.1.3	TE buffer	36
2.3	Polymerase chain reaction	36
2.3.1	PCR reagents	36
2.3.1.1	DNA polymerase	36
2.3.1.2	dNTP solution	36
2.3.1.3	10 x PCR buffer	36
2.3.1.4	Primers	37
2.3.2	Standard PCR reaction components	38
2.3.3	Gradient PCR thermal cycler settings	39
2.3.4	PCR direct from colony	40
2.3.5	Megaprimer PCR	41
2.3.6	Reverse Transcriptase PCR	41
2.3.6.1	DEPC treated H ₂ O	41
2.3.6.2	Total cDNA synthesis	41
2.3.6.3	Gene specific or mRNA specific cDNA synthesis	42
2.3.6.4	cDNA amplification	42
2.4	Restriction enzyme digestion of DNA	42
2.5	DNA ligation	43
2.6	Bacterial transformation	43
2.6.1	Blue white selection	44
2.6.2	Competent cells	44
2.7	DNA purification	44
2.7.1	Gel purification	44
2.7.2	PCR product purification	45
2.7.3	Phenol/chloroform purification of DNA	45
2.7.4	Plasmid DNA isolation	45

2.8	DNA quantitation	46
2.8.1	Fluorometric quantitation with hoechst dye	46
2.8.1.1	Hoechst dye stock	46
2.8.1.2	10 x TNE buffer	46
2.8.1.3	Working solution A	46
2.8.1.4	Fluorometric quantitation	46
2.8.2	Quantitation by ethidium bromide staining	46
2.9	Agarose gel electrophoresis	47
2.9.1	Agarose gel electrophoresis solutions	47
2.9.1.1	Ethidium bromide staining solution	47
2.9.1.2	SDS loading dye	47
2.9.1.3	1 x TAE electrophoresis buffer	47
2.9.1.4	1 x TBE electrophoresis buffer	47
2.9.2	Agarose gel electrophoresis method	47
2.10	Automated sequencing of DNA	48
2.11	Recombinant protein expression and analysis	48
2.11.1	Recombinant protein expression	48
2.11.2	Sample preparation for total protein analysis	48
2.11.3	Sample preparation for protein solubility analysis	49
2.11.4	Solubilisation of proteins with <i>n</i> -laurylsarkosine	49
2.12	Affinity chromatography	49
2.12.1	Affinity chromatography solutions	49
2.12.1.1	Glutathione elution buffer	49
2.12.1.2	Haemin solution	50
2.12.1.3	PreScission protease cleavage buffer	50
2.12.2	Binding of GST fusion proteins to affinity beads	50
2.12.3	Elution of GST fusion proteins from affinity beads	50
2.12.4	PreScission protease cleavage of GST fusion proteins	51

2.13 SDS Polyacrylamide gel electrophoresis

(SDS/PAGE)	51
2.13.1 SDS/PAGE solutions	51
2.13.1.1 Acrylamide bisacrylamide mix	51
2.13.1.2 Coomassie brilliant blue staining solution	51
2.13.1.3 Coomassie brilliant blue destaining solution	51
2.13.1.4 10 x protein electrophoresis buffer	52
2.13.1.5 2 x protein sample treatment buffer	52
2.13.1.6 6 x protein sample treatment buffer	52
2.13.2 Polyacrylamide gel components	52
2.13.3 Gel casting	52
2.13.4 Sample preparation for electrophoresis	53
2.13.5 SDS Polyacrylamide gel electrophoresis	53
2.13.6 Coomassie brilliant blue staining	53

2.14 Bioinformatics 53

2.14.1 Hydropathy analysis	53
2.14.2 Multiple sequence alignment	54

Chapter 3 Results 55

3.1 Construction of GST-PaxP and GST-PaxQ

expression vectors	56
3.1.1 Initial PCR amplification of <i>paxP</i> and <i>paxQ</i> cDNA	56
3.1.2 PCR amplification of <i>paxP</i> and <i>paxQ</i> from megaprimer cDNA template	56
3.1.2.1 The megaprimer method of PCR amplification	56
3.1.2.2 Design of <i>paxP</i> and <i>paxQ</i> megaprimers	58
3.1.2.3 Optimisation of megaprimer PCR conditions	60
3.1.2.4 A <i>paxQ</i> clone synthesised with megaprimer PCR	61

3.1.3	Comparison of three different methods of cDNA synthesis _____	62
3.1.3.1	Cloning of <i>paxP</i> cDNA _____	64
3.1.3.2	Cloning of <i>paxQ</i> cDNA _____	66
3.2	Recombinant expression of GST-<i>paxP</i> and GST-<i>paxQ</i> in <i>E. coli</i> _____	67
3.2.1	Expression of GST-PaxP from pRL2 _____	67
3.2.2	Analysis of the solubility of GST-PaxP and GST-PaxQ expressed in <i>E. coli</i> . _____	71
3.3	Solubilisation of GST-PaxP with <i>N</i>-laurylsarkosine _____	76
3.3.1	Overview of the solubilisation of insoluble proteins with <i>N</i> -laurylsarkosine _____	76
3.3.2	Determination of the minimum concentration of <i>N</i> -laurylsarkosine required to solubilise GST-PaxP _____	76
3.3.3	Determination of the minimum concentration of Triton X-100 required for affinity chromatography of solubilised GST-PaxP. _____	77
3.3.4	Addition of the haemin ligand to enhance affinity chromatography of GST-PaxQ _____	81
3.3.5	Recovery of GST-PaxQ from glutathione-affinity beads _____	83
3.4	Construction of N-terminal deletion PaxP and PaxQ expression vectors _____	85
3.4.1	The redesign of PaxP and PaxQ expression constructs _____	85
3.4.2	Construction of N-terminal modified PaxP and PaxQ GST fusion expression vectors _____	87
3.4.3	Solubility characteristics of N-terminal deleted PaxP and PaxQ as GST fusion proteins. _____	89
3.4.4	Construction of N-terminal modified PaxP and PaxQ Thioredoxin fusion expression vectors _____	91

3.4.5	Solubility characteristics of N-terminal deleted PaxP and PaxQ as Thioredoxin fusion proteins.	92
-------	--	----

Chapter 4 Discussion _____ 94

4.1 Expression of PaxP and PaxQ in *E. coli* _____ 95

4.1.1	The GroES/EL chaperones	96
-------	-------------------------	----

4.1.2	Disulphide bond formation	97
-------	---------------------------	----

4.2 Protein solubilisation and refolding _____ 98

4.2.1	Detergent mediated solubilisation	99
-------	-----------------------------------	----

4.2.2	Affinity chromatography of solubilised protein	100
-------	--	-----

4.3 N-terminal modification _____ 101

4.3.1	Insolubility characteristics of Δ 1-39PaxP and Δ 1-29PaxQ	102
-------	---	-----

4.4 Sequence alignment of PaxP and PaxQ _____ 103

4.4.1	Cytochrome P450 secondary structure	103
-------	-------------------------------------	-----

4.4.2	Redox partner interactions	105
-------	----------------------------	-----

4.4.3	The substrate binding site	106
-------	----------------------------	-----

4.5 Alternate strategies _____ 107

4.5.1	Functional analysis of PaxP and PaxQ	109
-------	--------------------------------------	-----

4.6 Summary _____ 112

Chapter 5 Bibliography _____ 114

Chapter 6 Appendix _____ 124

6.1 Vector maps _____ 125

6.1.1	pUC118	125
-------	--------	-----

6.1.2	pGEM-T-Easy	126
-------	-------------	-----

6.1.3	pThioHis A _____	127
6.1.4	pGEX-6P-3 _____	128
6.1.5	pGroESL _____	129
6.1.6	pSJS1240 _____	130
6.2	Automated sequencing chromatograms _____	131
6.2.1	Chromatogram: #1 _____	131
6.2.2	Chromatogram: #2 _____	132
6.2.3	Chromatogram: #3 _____	133
6.2.4	Chromatogram: #4 _____	134
6.2.5	Chromatogram: #5 _____	135
6.2.6	Chromatogram: #6 _____	136
6.2.7	Chromatogram: #7 _____	137
6.3	cDNA and deduced amino acid sequence of	
	<i>P. paxilli paxP</i> _____	138
6.4	cDNA and deduced amino acid sequence of	
	<i>P. paxilli paxQ</i> _____	142

Abbreviations

APS	ammonium persulphate
bp	base pairs
cDNA	complementary deoxyribonucleic acid
CPR	cytochrome P450 reductase
DEPC	diethylpyrocarbonate
DMAPP	dimethylallyldiphosphate
DNA	deoxyribonucleic acid
dNTP	deoxynucleotide triphosphate
dsDNA	double stranded deoxyribonucleic acid
DTT	dithiothreitol
EDTA	ethylenediaminetetraacetic acid
ER	endoplasmic reticulum
FAD	flavin adenine dinucleotide
FMN	flavin mononucleotide
FPP	farnesyl diphosphate
gDNA	genomic deoxyribonucleic acid
GGPP	geranylgeranyl diphosphate
GST	glutathione-s-transferase
HMG-CoA	3-hydroxy-3-methylglutaryl coenzyme A
IPP	isopentenyl diphosphate
IPTG	isopropylthiogalactoside
kb	kilobase pairs
LB media	Luria Bertaini media
MCS	multiple cloning site
mRNA	messenger ribonucleic acid
NADH	nicotinamide adenine dinucleotide
NADPH	nicotinamide adenine dinucleotide phosphate
PAGE	polyacrylamide gel electrophoresis
PCR	Polymerase chain reaction
psi	pounds per square inch
RNA	ribonucleic acid

RT-PCR	reverse-transcriptase polymerase chain reaction
SDS	sodium dodecyl sulphate
SRS	substrate recognition site
TEMED	tetramethylethylenediamine
tRNA	transfer ribonucleic acid
UV	ultra violet
X-Gal	5-Bromo-4-chloro-3-indolyl-beta-D-galactoside

List of tables

Table 2.1	Plasmids	35
Table 2.2	Primers	37
Table 2.3	Thermal cycler settings	39

List of Figures

Figure 1.1	The structures of indole diterpenoids	3
Figure 1.2	Isoprenoid biosynthesis	6
Figure 1.3	Proposed scheme for paxilline bioynthesis	10
Figure 1.4	Overview of the paxilline biosynthetic gene cluster	11
Figure 1.5	The substrates of various cytochrome P450 enzymes	13
Figure 1.6	The cytochrome P450 reaction cycle and haem cofactor	15
Figure 1.7	Overview of available cytochrome P450 enzyme structures	17
Figure 1.8	Overview of the P450BM-3 haem domain structure	19
Figure 1.9	Orientation of membrane bound P450s	22
Figure 1.10	Sequence alignment of fungal cytochrome P450 enzymes	24
Figure 2.1	The gradient PCR heating block	40
Figure 3.1	Strategy to clone a full length cDNA copy of <i>paxP</i> and <i>paxQ</i>	57
Figure 3.2	PCR amplification of <i>paxP</i> and <i>paxQ</i> from random hexamer and gene specific cDNA	58

Figure 3.3	Overview of the megaprimer method of PCR amplification	59
Figure 3.4	Optimisation of PCR conditions for <i>paxP</i> and <i>paxQ</i> megaprimer synthesis	60
Figure 3.5	Comparison of gene specific, random hexamer and oligo dT primers for cDNA synthesis	62
Figure 3.6	PCR amplification of <i>paxP</i> from gene specific cDNA	63
Figure 3.7	PCR amplification of <i>paxQ</i> from oligo dT primed cDNA	64
Figure 3.8	PCR cycle optimisation for <i>paxQ</i> amplification	65
Figure 3.9	PCR amplification of <i>paxQ</i> for cloning	66
Figure 3.10	Rare codon usage in <i>paxP</i> and <i>paxQ</i>	69
Figure 3.11	GST-PaxP expression supplemented with tRNA genes for rare <i>E. coli</i> codons	70
Figure 3.12	Solubility characteristics of GST-PaxP when expressed at 18°C, 25°C and 37°C	72
Figure 3.13	Solubility characteristics of GST-PaxQ when expressed at 25°C and 37°C	73
Figure 3.14	Co-overexpression of GroES and GroEL <i>E. coli</i> chaperones with GST-PaxP	74
Figure 3.15	Solubility characteristics of GST-PaxP when expressed in Origami B <i>E. coli</i> at 18°C and 25°C	75
Figure 3.16	The effect of <i>N</i> -laurylsarkosine on the solubility of GST-PaxP	77
Figure 3.17	The effect of Triton X-100 on affinity chromatography of solubilised GST and GST-PaxP	78
Figure 3.18	The effect of Triton X-100 on modified affinity chromatography of solubilised GST and GST-PaxP	79
Figure 3.19	The effect of affinity bead volume on affinity chromatography of solubilised GST and GST-PaxP	80
Figure 3.20	The effect of haemin on affinity chromatography of solubilised GST-PaxQ	82

Figure 3.21	Elution of GST-PaxQ from glutathione-sepharose affinity beads	83
Figure 3.22	Digestion of GST-PaxP bound to affinity chromatography beads	84
Figure 3.23	Hydrophobicity analysis of the N-terminal regions of PaxP and PaxQ	86
Figure 3.24	Strategy to construct N-terminal deleted PaxP and PaxQ expression vectors	88
Figure 3.25	Solubility characteristics of GST- Δ 1-39PaxP when expressed at 15°C, 22°C and 37°C	89
Figure 3.26	Solubility characteristics of GST- Δ 1-29PaxQ when expressed at 15°C, 22°C and 37°C	90
Figure 3.27	Solubility characteristics of Thio- Δ 1-39PaxP when expressed at 15°C, 22°C and 37°C	92
Figure 3.28	Solubility characteristics of Thio- Δ 1-29PaxQ when expressed at 15°C, 22°C and 37°C	93
Figure 4.1	Comparison of progesterone and paxilline biosynthesis	106